Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Newsletter IMODI #5 - April 2018


Published on

ZOOM: Pancreatic Cancer
• NEWS: Publication by Juan IOVANNA
• IMODI around the world: Meet the experts!
• FOCUS: From the bench to the bedside, INSERM U1068
• WEB-CATALOGUE: 20 in-vitro cell models available

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Newsletter IMODI #5 - April 2018

  1. 1. NEWSLETTER n°5 - April 2018 ZOOM: Pancreatic Cancer • NEWS: Publication by Juan IOVANNA • IMODI around the world: Meet the experts! • FOCUS: From the bench to the bedside, INSERM U1068 • WEB-CATALOGUE: 20 in-vitro cell models available Pancreatic Ductal AdenoCarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem, causing around 350,000 deaths per year worldwide. The prognosis is poor, with around 5% of patients alive at 5 years after diagnosis. Over recent decades, detailed genetic analysis of tumors has resulted in the identification and validation of crucial genes that are mutated and dysregulated in a tumor-specific manner, indicating a genetic dependency in the development of these tumors, and suggesting that it could be possible to take advantage of these mutations as potential therapeutic targets, where specific drugs are available. Unfortunately, after a highly enthusiastic period, we must recognize that these types of targets can be effectively utilized for only a small percentage of patients; firstly, because relevant drugs are not available, and secondly, because the mutated genes are not druggable. This is the case for PDAC, in which the mutations are relatively conserved between tumors (KRAS, P53, SMAD4, CDKN2A, MLL3, TGFBR2, ARID1A, and SF3B1) but targetable genes remain extremely rare since some of them do not present direct enzymatic activity to be inhibited or because their protein-protein interaction-based activity remain technically unattainable for the moment.Almost all recent phase II and III clinical trials implemented in unselected PDAC populations showed no robust survival benefits, probably because they were tested in unselected PDAC populations that were highly heterogeneous. In fact, a major impediment to the effective treatment of PDAC is the molecular heterogeneity of the disease, reflected in diverse clinical response patterns to therapy. (...) A major obstacle for efficient treatment of PDAC is its molecular heterogeneity reflected by the variable clinical evolution. The starting point of this project was precisely the heterogeneity observed in the clinical outcome of PDAC patients, the variable survival time after diagnosis and a strong difference in the sensibility of tumors to treatments. We hypothesized that “deep and systematic”studiesbyusing“Omics”approachesshouldallowustoi/classifytumors;ii/ identify the most effective and specific targets for each patient, and iii/ to identify clinically useful biomarkers. JoinServier&OncodesignattheAACRCongress:April14-18,Chicago,USA.Oncodesign will be present with a booth plus an outstanding series of posters and a talk (booth #1946) Oncodesign will participate to the European Partnering Convention called MEET2WIN entirely dedicated to open innovation and collaborative research in oncology - 17-18 May, Bordeaux Servier (Alain BRUNO) will be present at ASCO Annual Meeting: June 1-5, Chicago, USA Join Biofortis (Françoise LE VACON) at the 7th International Human Microbiome Congress 2018 (IHMC): June 26-28, Killarney, Kerry Ireland  Pancreatic Cancer: what’s new? Take an alternative road with Juan Iovanna’s team to individualized pancreatic cancer treatments Meet OUR experts Read the article Read the article Where to meet our experts ZOOMNEWSIMODI AROUNDTHEWORLD © IMODI Cancer - April 2018 - All right reserved - - news@imodi-cancer.frPage 1 on 2 Next > Dr Juan IOVANNA - CRCM U1068 ©Divergenceimages MEETING   
  2. 2. NEWSLETTER n°5 - April 2018 The french IMODI (Innovative MODels Initiative) consortium is dedicated to the development, the characterization and the commercialization of new preclinical models in oncology. IMODI is a public-private consortium of 18 partners pooling their ressources for the development of more valuable models of cancer in order to decrease the attrition rate of clinical development of novel anti-cancer agents. Science and technology developments: The Centre de Recherche en Cancerologie de Marseille (CRCM) goal is to develop cutting edge cancer research from the bench to the bedside. Since its creation, the CRCM develops an integrated cancer research program, from basic science to translational medicine and clinical research, which is unique in Marseille. Their main scientific and medical specialities are the molecular basis of oncogenesis, tumor dissemination and host response on the one hand, and the development of innovative therapeutics mostly in breast cancer, pancreatic cancer and malignant hemopathies. All the 19 teams of the CRCM are internationally recognized and affiliated with INSERM, CNRS and Aix- Marseille University. The Pancreatic Cancer team, directed by Juan Iovanna, at the CRCM, is interested in the molecular aspects of the pancreatic ductal adenocarcinoma development and progression and to improve the current available therapeutic approaches and, more particularly, in developing tools and strategies towards personalized treatments. The team was centered the subjects of interest on three main areas: 1/ signalization and metabolism of the pancreatic cancer cells; 2/ the role of intra- tumoral microenvironment in PDAC carcinogenesis; and finally 3/ on translational medicine by developing an exceptional molecularly and functionally well characterized PDTX collection from 200 patients and a collection of primary organoids. Concerning these last approaches the team focuses on a systematic characterization on DNA, RNA and proteins as well as metabolites and epigenomics modifications. On the other hand, the establishment of a chemogram, by analogy with the antibiogram for microorganisms, allows the identification of the most efficient anticancer drug for a given patient. (...) IMODI at a glance Model and treat the diversity of cancers From bench to the bedside: Inserm U1068 Research lab Read detailled article 2013/01/01: Creation of the consortium 2013/09/01:Signature of the consortium agreement 2015/10/01:Signature of the 1st licence agreement 7 years: duration of the 1rst R&D phase 150 Researchers 6 SMEs 4 pharmaceutical industries 8 Academic institutions FOCUS © IMODI Cancer - April 2018 - All rights reserved - - Developing PDX models and cellular assays Modelling the human tumour microenvironment in mice Studying the relationship between microbiota and cancer Designedby:EssentielMARKETING IMODI’s partners 20 in-vitro cell models are already available for various cancers studied in the IMODI consortium with new models and characterization data being added every month. The IMODI in-vitro cell models retain the properties of patient tumor and allow highly reproductible studies providing understanding in cell biology, drug sensitivity and insight into signaling pathways. Do not hesitate to contact CTIBiotech for In-vitro Patient and PDX Derived Cancer Cell Models ; a full list of the models will be available in the IMODI Web catalogue in the coming weeks. New in vitro characterized models Discover WEB-CATALOGUE in-vitro cell models Several Patient Derived Cell models are already being used in the 3D-OncoCHIP FUI Project lead by CTIBiotech aiming to develop 3D printing techniques to produce reproducible microtumors and their microenvironment. >> Learn more about 3D printing of tumoral models and 3D-OncoCHIP